Melane Sampson, Author at BioTuesdays

Developments

OS to spin off OSAH into a standalone company

OS Therapies (NYSE American: OSTX) has announced its intent to spin off OS Animal Health (OSAH)—the company’s wholly owned subsidiary developing OST-HER2 for canine osteosarcoma—into a standalone public company...

November 20, 2025

Developments

Profound celebrates The Hong Center’s 200th independent TULSA procedure; Dr. Mark Hong sees TULSA ultimately replacing radical prostatectomy as a first-line option for prostate cancer

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA...

November 18, 2025

Developments

Quanterix highlights landmark study published in Brain validating dual approach for personalized MS monitoring

Quanterix (NASDAQ: QTRX) has announced the publication of a landmark study in the peer-reviewed scientific journal Brain, validating that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and...

November 18, 2025

Developments

Modular receives IRB approval to deliver insulin via Pivot patch pump

Modular Medical (NASDAQ: MODD) has announced that the Institutional Review Board (IRB) has granted approval to conduct an in-house study of its next-generation Pivot insulin delivery system using insulin on people with...

November 17, 2025

Developments

Adaptimmune reports changes to BOD and leadership team

Adaptimmune Therapeutics (OTC PINK: ADAPY) has announced changes to its board of directors (BOD) and leadership team effective November 14, 2025, following the voluntary delisting of the company’s American Depository...

November 17, 2025

Developments

Zynex announces a series of strategic initiatives

Zynex (NASDAQ: ZYXI) has announced the engagement of financial advisory firm Province LLC, the appointment of Paul Aronzon to its board of directors, and the formation of a special committee. Mr. Paul Aronzon brings...

November 14, 2025

Developments

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that total revenues for the third quarter of 2025 were $5.3 million, representing year-over-year revenue growth of 87%. The gross margin for the third quarter of 2025...

November 13, 2025

Developments

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing, FDA-regulated Phase 1/2a clinical trial evaluating...

November 13, 2025

Developments

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO system with closely held Getz Healthcare, a leading distributor of...

November 12, 2025

Developments

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical...

November 11, 2025

Author - Melane Sampson

OS to spin off OSAH into a standalone company

Profound celebrates The Hong Center’s 200th independent TULSA procedure; Dr. Mark Hong sees TULSA ultimately replacing radical prostatectomy as a first-line option for prostate cancer

Quanterix highlights landmark study published in Brain validating dual approach for personalized MS monitoring

Modular receives IRB approval to deliver insulin via Pivot patch pump

Adaptimmune reports changes to BOD and leadership team

Zynex announces a series of strategic initiatives

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Subscribe